AVITA MEDICAL INC (AVH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

AVH - AVITA MEDICAL INC

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences

Year End: December

GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences

Debt/EBITDA: -0.88

Index: ALL-ORDS

Avita Medical is developing and marketing a range of regenerative skin products. It is headquartered in California and listed on the ASX and NASDAQ.

LAST PRICE	CHANGE +/-	CHANGE %	VOLUME
$1.45 22 Aug 2025	-0.020 OPEN $1.48	-1.36% HIGH $1.48	649,016 LOW $1.45

TARGET

$1.75

20.7% upside

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .

FNARENA'S MARKET CONSENSUS FORECASTS

12 Month Avg FX Values

Present FX Values

Original Currency

Title	FY25 Forecast	FY26 Forecast
EPS (cps)	- 101.0	xxx
DPS (cps)	0.0	xxx
EPS Growth	N/A	xxx
DPS Growth	N/A	xxx
PE Ratio	N/A	xxx
Dividend Yield	0.0%	xxx
Div Pay Ratio(%)	N/A	xxx

Title	FY25 Forecast	FY26 Forecast
EPS (cps)	- 101.5	xxx
DPS (cps)	0.0	xxx
EPS Growth	N/A	xxx
DPS Growth	N/A	xxx
PE Ratio	N/A	xxx
Dividend Yield	0.0%	xxx
Div Pay Ratio(%)	N/A	xxx

Title	FY23 Actual	FY24 Actual	FY25 Forecast	FY26 Forecast
EPS (cps)	xxx	- 238.0	- 65.3	xxx
DPS (cps)	xxx	0.0	0.0	xxx
EPS Growth	xxx	N/A	N/A	xxx
DPS Growth	xxx	N/A	N/A	xxx
Div Pay Ratio(%)	xxx	N/A	N/A	xxx

This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

HISTORICAL DATA ARE ALL IN AUD

Copyright © 2025 FactSet UK Limited. All rights reserved

Title	2019	2020	2021	2022	2023	2024
EPS Basic	xxx	xxx	xxx	xxx	xxx	-72.5
DPS All	xxx	xxx	xxx	xxx	xxx	0.0
Sales/Revenue	xxx	xxx	xxx	xxx	xxx	97.4 M
Book Value Per Share	xxx	xxx	xxx	xxx	xxx	5.5
Net Operating Cash Flow	xxx	xxx	xxx	xxx	xxx	-74.2 M
Net Profit Margin	xxx	xxx	xxx	xxx	xxx	-96.26 %

EPS Basic

Negative
Growth
Slowing

DPS All

Negative
Growth
Slowing

Sales/Revenue

Negative
Growth
Slowing

Book Value Per Share

Negative
Growth
Slowing

Net Operating Cash Flow

Negative
Growth
Slowing

Net Profit Margin

Negative
Growth
Slowing

Title	2019	2020	2021	2022	2023	2024
Return on Capital Employed	xxx	xxx	xxx	xxx	xxx	-236.89 %
Return on Invested Capital	xxx	xxx	xxx	xxx	xxx	-88.11 %
Return on Assets	xxx	xxx	xxx	xxx	xxx	-64.14 %
Return on Equity	xxx	xxx	xxx	xxx	xxx	-236.89 %
Return on Total Capital	xxx	xxx	xxx	xxx	xxx	-79.48 %
Free Cash Flow ex dividends	xxx	xxx	xxx	xxx	xxx	-88.1 M

Return on Capital Employed

Negative
Growth
Slowing

Return on Invested Capital

Negative
Growth
Slowing

Return on Assets

Negative
Growth
Slowing

Return on Equity

Negative
Growth
Slowing

Return on Total Capital

Negative
Growth
Slowing

Free Cash Flow ex dividends

Negative
Growth
Slowing

Title	2019	2020	2021	2022	2023	2024
Short-Term Debt	xxx	xxx	xxx	xxx	xxx	1 M
Long Term Debt	xxx	xxx	xxx	xxx	xxx	73 M
Total Debt	xxx	xxx	xxx	xxx	xxx	74 M
Goodwill - Gross	xxx	xxx	xxx	xxx	xxx	-
Cash & Equivalents - Generic	xxx	xxx	xxx	xxx	xxx	58 M
Price To Book Value	xxx	xxx	xxx	xxx	xxx	77.08

Short-Term Debt

Negative
Growth
Slowing

Long Term Debt

Negative
Growth
Slowing

Total Debt

Negative
Growth
Slowing

Goodwill - Gross

Cash & Equivalents - Generic

Negative
Growth
Slowing

Price To Book Value

Negative
Growth
Slowing

Title	2019	2020	2021	2022	2023	2024
Capex	xxx	xxx	xxx	xxx	xxx	14.1 M
Capex % of Sales	xxx	xxx	xxx	xxx	xxx	14.53 %
Cost of Goods Sold	xxx	xxx	xxx	xxx	xxx	14 M
Selling, General & Admin. Exp & Other	xxx	xxx	xxx	xxx	xxx	169 M
Research & Development	xxx	xxx	xxx	xxx	xxx	31 M
Investments - Total	xxx	xxx	xxx	xxx	xxx	0 M

Capex

Negative
Growth
Slowing

Capex % of Sales

Negative
Growth
Slowing

Cost of Goods Sold

Negative
Growth
Slowing

Selling, General & Admin. Exp & Other

Negative
Growth
Slowing

Research & Development

Negative
Growth
Slowing

Investments - Total

Negative
Growth
Slowing

Negative

Growth

Slowing

EXPERT VIEWS
EXTRA COVERAGE

EXPERT VIEWS

Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
Bell Potter	xx/xx/xxxx	5	xxxxxxxxx xx xxxx xxxx xxxx	$xx.xx	xx.xx%	Broker commentary and detailed analysis is available for Full Members Only. Login above or Get a Free Trial
Morgans	11/08/2025	1	Speculative Buy	$2.00	37.93%	Morgans has repeated its assessment from Friday: Avita Medical's 2Q25 report represents a significant miss versus expectations. Morgans points out there was no sales growth on the quarter as delays and complications continue to secure reimbursement from the regional Medicare contractors. Management has been forced to make large downgrades to guidance, and pushed guidance around profitability to the middle of next year. The broker finds solace in the fact management has successfully rolled through cost-base reductions, as planned, decreasing the net loss with more to come in 3Q. Alas, Morgans now also believes another capital raising will be necessary to successfully lead this company to profitability. Reduced forecasts have pulled back the price target to $2 from $3.76 prior. Speculative Buy rating retained with the comment that both balance sheet and execution risks have increased. FORECAST Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -40.41 cents. Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -18.11 cents.

BROKER

DATE

RATING

RECOMMENDATION

TARGET PRICE

% TO REACH TARGET

COMMENTARY

Bell Potter

xx/xx/xxxx

xxxxxxxxx xx xxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

11/08/2025

Speculative Buy

$2.00

37.93%

Morgans has repeated its assessment from Friday: Avita Medical's 2Q25 report represents a significant miss versus expectations.

Morgans points out there was no sales growth on the quarter as delays and complications continue to secure reimbursement from the regional Medicare contractors.

Management has been forced to make large downgrades to guidance, and pushed guidance around profitability to the middle of next year.

The broker finds solace in the fact management has successfully rolled through cost-base reductions, as planned, decreasing the net loss with more to come in 3Q.

Alas, Morgans now also believes another capital raising will be necessary to successfully lead this company to profitability.

Reduced forecasts have pulled back the price target to $2 from $3.76 prior. Speculative Buy rating retained with the comment that both balance sheet and execution risks have increased.

FORECAST
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -40.41 cents.
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -18.11 cents.

Access Stockbroker Research History >

EXTRA COVERAGE

Display All Commentary

No. Of Recommendations

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER	DATE	RATING	RECOMMENDATION	TARGET PRICE	% TO REACH TARGET	COMMENTARY
Wilsons	13/08/2025	5	Underweight	$1.25	-13.79%	Avita Medical cut its 2025 guidance by -24% to US$76m–US$81m, with 2Q2025 revenue of US$18.4m missing Wilsons' forecast by -20% and consensus by -23% due to CMS' coding and payment practices being "dislocated" for Recell over the quarter. Providers lowered Recell re-orders as a result of denial of consistent payments, which, as the analyst explains, is “understandable.” Medicare Administrative Contractors are due to restart Recell claims adjudication and payments during 3Q2025. Due to the deferral in GAAP net profit after tax, now targeted for 3Q2026, and cash flow breakeven in 2Q2026, with US$42m in debt moved to current liabilities, Wilsons estimates a capital requirement of US$75m to repay debt and keep Avita's assets ongoing. Underweight rating retained. Target price falls another -35% to $1.25, Wilsons bemoans. FORECAST Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -28.33 cents. Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -16.10 cents.

BROKER

DATE

RATING

RECOMMENDATION

TARGET PRICE

% TO REACH TARGET

COMMENTARY

Wilsons

13/08/2025

Underweight

$1.25

-13.79%

Avita Medical cut its 2025 guidance by -24% to US$76m–US$81m, with 2Q2025 revenue of US$18.4m missing Wilsons' forecast by -20% and consensus by -23% due to CMS' coding and payment practices being "dislocated" for Recell over the quarter.

Providers lowered Recell re-orders as a result of denial of consistent payments, which, as the analyst explains, is “understandable.” Medicare Administrative Contractors are due to restart Recell claims adjudication and payments during 3Q2025.

Due to the deferral in GAAP net profit after tax, now targeted for 3Q2026, and cash flow breakeven in 2Q2026, with US$42m in debt moved to current liabilities, Wilsons estimates a capital requirement of US$75m to repay debt and keep Avita's assets ongoing.

Underweight rating retained. Target price falls another -35% to $1.25, Wilsons bemoans.

FORECAST
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -28.33 cents.
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -16.10 cents.

Access Extra Coverage Research History >

AVH STOCK CHART

FNArena News on AVH

1	Rudi’s View: Early August Signals & Observations Aug 20 2025 - Rudi's View

2	Next Week At A Glance – 18-22 Aug 2025 Aug 15 2025 - Weekly Reports

3	Australian Broker Call Extra Edition – Aug 13, 2025 Aug 13 2025 - Daily Market Reports

4	FNArena Corporate Results Monitor – 11-08-2025 Aug 11 2025 - Australia

5	Rudi’s View: Extreme Bifurcation Ahead Of August Jul 23 2025 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1	Earnings Result Leaves CSL Bloodied Aug 21 2025 - Australia

2	Renewed Momentum For CSL Shares Jul 22 2025 - Technicals

3	Treasure Chest: CSL Not A One-Trick Pony Jul 14 2025 - Treasure Chest

4	The Enigma Surrounding Clinuvel Jul 03 2025 - Small Caps

5	Rudi’s View: CSL & NextDC May 08 2025 - Rudi's View

6	Behring Margin Outlook Still Main Game For CSL Feb 13 2025 - Australia

7	Dr Boreham’s Crucible: Arovella Therapeutics Aug 29 2024 - Small Caps

8	ResMed’s Margin Upside Excites Aug 07 2024 - Australia

9	Dr Boreham’s Crucible: Aroa Biosurgery Jul 29 2024 - Small Caps

10	CSL Shares Breaking Free Jul 23 2024 - Technicals

Dividend Yield Today On Last Actual Payout :	N/A
Estimated Dividend Growth (Average Of Past Three Years)	%
Amount Invested	$
Tell Me The Dividend After This Many Years

	Yield	Yield on investment
This Year
Year 1
Year 2
Year 3
Year 4
Year

Get 2 Weeks free trial

Sign Up

Member Login

AVITA MEDICAL INC (AVH)
Share Price Analysis and Chart